Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 5/20 | 0.39 |
| ▸ | RAF1 | P04049 | 8/20 | 0.34 |
| ▸ | BRAF | P15056 | 8/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.32 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.32 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.31 |
| ▸ | EGFR | P00533 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2973501 | 0.93 | ADORA1 (0.39) | ADORA1RAF1BRAFFGFR1ERN1 | |
| SCHEMBL2980178 | 0.91 | HSD17B1 (0.40) | ADORA1RAF1BRAFFGFR1ERN1 | |
| SCHEMBL2981681 | 0.89 | ADORA1 (0.39) | ADORA1RAF1BRAFFGFR1ERN1 | |
| SCHEMBL5149006 | 0.87 | ADORA1 (0.39) | ADORA1RAF1BRAFFGFR1ERN1 | |
| SCHEMBL2978018 | 0.87 | HSD17B1 (0.39) | ADORA1RAF1BRAFFGFR1ERN1 | |
| SCHEMBL2972000 | 0.85 | RAF1 (0.35) | ADORA1RAF1BRAFFGFR1ERN1 | |
| SCHEMBL2975277 | 0.83 | KDR (0.38) | ADORA1RAF1BRAFMAPK8KDR | |
| SCHEMBL2977467 | 0.82 | GRIN1 (0.32) | GRIN1GRIN2B | |
| SCHEMBL2987614 | 0.81 | ADORA1 (0.36) | ADORA1RAF1BRAFFGFR1ERN1 | |
| SCHEMBL2981953 | 0.80 | ADORA1 (0.41) | ADORA1FGFR1ABL1MAPK14EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831207-B1 | AMINOPYRIMIDINE COMPOUNDS AS PLK INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| US-7858785-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7786132-B2 | Aminopyrimidine compounds and methods of use | AMGEN INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2010-01-14 | — | — | US | disclosed |
| EP-1831207-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | Amgen Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | AMGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2006066172-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010014-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE | PLK1, TYMP, TK2 | ADORA1 1406/4885RAF1 1089/4885BRAF 841/4885 |
| US-20070185133-A1 | Aminopyrimidine compounds and methods of use | PLK1, TYMP, TK2 | ADORA1 1406/4885RAF1 1089/4885BRAF 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.